The effect of Plasmapheresis in the treatment of patients with COVID-19
- Conditions
- COVID-19.COVID-19U07.1
- Registration Number
- IRCT20200611047735N2
- Lead Sponsor
- Bandare-abbas University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 45
COVID-19 patients with positive Realtime PCR test for COVID-19
tachypnea> Respiratory Rate 30 per minute and dyspnea, Oxygen saturation lower than 88% and fraction of inspired oxygen/ PaO2 ratio lower to equal 300, and increased lung involvement by more than 50% on CT scan.
Patient with symptoms of respiratory failure, patient in need or under mechanical ventilation, patient with multiple organ failure and patient with shock symptoms
Presence of two positive inflammatory markers including: Ferritin greater than 1000 or CRP above 50 mg/dl or ' ' +++ ' ' or Lactate dehydrogenase greater than 1000
Lack of proper response to antiviral and corticosteroid therapy and hypoxia during hospitalization
Low blood pressure lower than normal range, which causes a further decrease in blood pressure during plasmapheresis.
Coagulation disorders that cause bleeding during plasmapheresis.
Decreased blood platelets below the normal range, which may increase bleeding during plasmapheresis.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum IL-6 levels. Timepoint: Before plasmapheresis and after the last stage of plasmapheresis. Method of measurement: ELISA technique.;Serum IL-1ß levels. Timepoint: Before plasmapheresis and after the last stage of plasmapheresis. Method of measurement: ELISA technique.;Serum TNF-a levels. Timepoint: Before plasmapheresis and after the last stage of plasmapheresis. Method of measurement: ELISA technique.;Serum IFN-? levels. Timepoint: Before plasmapheresis and after the last stage of plasmapheresis. Method of measurement: ELISA technique.;Clinical manifestation. Timepoint: Before plasmapheresis and after the last stage of plasmapheresis. Method of measurement: Clinical examination and completion of a questionnaire.;Inflammatory factors of peripheral blood. Timepoint: Before plasmapheresis and after the last stage of plasmapheresis. Method of measurement: Peripheral blood test.
- Secondary Outcome Measures
Name Time Method